The stock of Allergan plc Ordinary Shares (NYSE:AGN) hit a new 52-week low and has $179.26 target or 8.00% below today’s $194.85 share price. The 8 months bearish chart indicates high risk for the $78.35 billion company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $179.26 price target is reached, the company will be worth $6.27B less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 2.41 million shares traded hands. Allergan plc Ordinary Shares (NYSE:AGN) has declined 26.19% since April 1, 2016 and is downtrending. It has underperformed by 27.40% the S&P500.
Allergan plc Ordinary Shares (NYSE:AGN) Ratings Coverage
Out of 17 analysts covering Allergan Inc. (NYSE:AGN), 13 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 76% are positive. Allergan Inc. has been the topic of 44 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by Mizuho given on Wednesday, April 6. Leerink Swann maintained Allergan plc Ordinary Shares (NYSE:AGN) rating on Tuesday, July 28. Leerink Swann has “Outperform” rating and $388 price target. As per Friday, August 5, the company rating was maintained by Mizuho. Mizuho maintained it with “Buy” rating and $299 target price in Tuesday, October 11 report. The firm has “Buy” rating given on Monday, September 21 by Leerink Swann. The stock of Allergan plc Ordinary Shares (NYSE:AGN) earned “Buy” rating by S&P Research on Friday, October 30. The firm earned “Buy” rating on Tuesday, November 1 by Mizuho. Leerink Swann maintained Allergan plc Ordinary Shares (NYSE:AGN) rating on Wednesday, October 28. Leerink Swann has “Outperform” rating and $342.0 price target. Mizuho upgraded the stock to “Buy” rating in Friday, August 19 report. On Friday, February 19 the stock rating was initiated by Wells Fargo with “Outperform”.
According to Zacks Investment Research, “Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment decreased to 0.46 in Q2 2016. Its down 0.29, from 0.75 in 2016Q1. The ratio fall, as 11 funds sold all Allergan plc Ordinary Shares shares owned while 2 reduced positions. 3 funds bought stakes while 3 increased positions. They now own 58,328 shares or 8.83% less from 63,978 shares in 2016Q1.
Grassi, a California-based fund reported 5,125 shares. Connors Investor has invested 0.04% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN). Frontier Mngmt has 0.94% invested in the company for 32,758 shares. Armstrong Henry H Associates accumulated 0.17% or 3,690 shares. Dowling And Yahnke Ltd Liability Com has 0.06% invested in the company for 2,145 shares. Moreover, Mitchell Mcleod Pugh Williams has 0.83% invested in Allergan plc Ordinary Shares (NYSE:AGN) for 3,975 shares. Marshwinds Advisory has 927 shares for 0.1% of their US portfolio. Mengis Cap Mngmt reported 6,210 shares or 1.27% of all its holdings. Gemmer Asset Limited Liability Com reported 127 shares or 0.02% of all its holdings. Chartist Inc Ca accumulated 0% or 1,844 shares. The Ohio-based Bartlett Co Limited Company has invested 0.01% in Allergan plc Ordinary Shares (NYSE:AGN). American Rech Management Communications holds 0% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN) for 33 shares.
More important recent Allergan plc Ordinary Shares (NYSE:AGN) news were published by: Investorplace.com which released: “Why Valeant Pharmaceuticals Intl Inc (VRX), Allergan plc Ordinary Shares (AGN …” on November 02, 2016, also Schaeffersresearch.com published article titled: “The Level Options Traders are Watching After Allergan plc Ordinary Shares (AGN …”, Investorplace.com published: “Allergan plc Ordinary Shares: What Is AGN Getting for Its Billion Dollars?” on September 20, 2016. More interesting news about Allergan plc Ordinary Shares (NYSE:AGN) was released by: Valuewalk.com and their article: “Allergan plc Ordinary Shares (AGN) Collapses On Treasury Ruling, Analysts React” with publication date: April 05, 2016.
AGN Company Profile
Allergan plc, incorporated on May 16, 2013, is a specialty pharmaceutical company. The Firm is engaged in the development, manufacturing, marketing and distribution of pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company’s divisions are US Brands, US Medical Aesthetics and International Brands. The US Brands segment includes sales and expenses relating to branded products within the United States, including certain Botox therapies. The US Medical Aesthetics segment includes sales and expenses relating to aesthetics and dermatology products within the United States, including certain Botox therapies. The International Brands segment includes sales and expenses relating to products sold outside of the United States. The Firm has global rights to RST-001, a gene therapy approach for the potential treatment of retinitis pigmentosa (RP). The RST-001 optogenetic approach includes a photosensitivity gene, channelrhodopsin-2, to create new photosensors in retinal ganglion cells to restore vision in retinal degenerative conditions. The RST-001 is in Phase I/IIa clinical trials. It has global rights to AKN-083, a preclinical farnesoid X receptor (FXR) agonist for the treatment of non-alcoholic steatohepatitis (NASH).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.